Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.47 |
| ▸ | CHRNG | P07510 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | CHRND | Q07001 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21236150 | 1.00 | FFAR1 (0.51) | FFAR1SLC6A3SLC6A2SLC6A4CHRNA1 | |
| SCHEMBL4203173 | 1.00 | FFAR1 (0.51) | FFAR1SLC6A3SLC6A2SLC6A4CHRNA1 | |
| SCHEMBL14306846 | 0.87 | FFAR1 (0.51) | FFAR1FFAR4ADORA2ACYP4F2CYP4A11 | |
| SCHEMBL29488083 | 0.85 | FFAR1 (0.50) | FFAR1FFAR4CYP4F2CYP4A11SLC9A1 | |
| SCHEMBL7655989 | 0.85 | FFAR1 (0.50) | FFAR1FFAR4CYP4F2CYP4A11SLC9A1 | |
| SCHEMBL248385 | 0.85 | FFAR1 (0.50) | FFAR1FFAR4CYP4F2CYP4A11SLC9A1 | |
| SCHEMBL18272446 | 0.85 | FFAR1 (0.50) | FFAR1FFAR4CYP4F2CYP4A11SLC9A1 | |
| SCHEMBL248384 | 0.85 | FFAR1 (0.50) | FFAR1FFAR4CYP4F2CYP4A11SLC9A1 | |
| SCHEMBL15196464 | 0.85 | FFAR1 (0.50) | FFAR1FFAR4CYP4F2CYP4A11SLC9A1 | |
| SCHEMBL12915852 | 0.85 | FFAR1 (0.50) | FFAR1FFAR4CYP4F2CYP4A11SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-02-05 | — | — | US | claimed |
| EP-1996560-A1 | QUINAZOLINONES AND THEIR USE AS POTASSIUM CHANNELS ACTIVATORS | NeuroSearch A/S (DK) | 2008-12-03 | — | — | EP | claimed |
| WO-2007104717-A1 | QUINAZOLINONES AND THEIR USE AS POTASSIUM CHANNELS ACTIVATORS | NEUROSEARCH A/S (DK) | 2007-09-20 | — | — | WO | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-1996560-A1 | QUINAZOLINONES AND THEIR USE AS POTASSIUM CHANNELS ACTIVATORS | NeuroSearch A/S (DK) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007104717-A1 | QUINAZOLINONES AND THEIR USE AS POTASSIUM CHANNELS ACTIVATORS | NEUROSEARCH A/S (DK) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | KCNK17, KCNN3, KCNA7 | FFAR1 2816/4885SLC6A3 240/4885SLC6A2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.